gwpharma-logoGW Pharmaceuticals, PLC is a company that specializes in the researching, manufacturing, and commercializing of prescription medicines that are cannabinoid-based with controlled substances, and plant-based pharmaceutical products that meet the needs of patients in a wide range of therapeutic conditions. GW Pharmaceuticals is listed in the NASDAQ Global Market under the symbol GWPH. It is also listed on AIM, a market of the London Stock Exchange.

The biopharmaceutical company, based in the United Kingdom, maintains internal control over every aspect of the development process of their cannabinoid products, from botanical research and drug formulation, to clinical trials and regulatory affairs.

Ever since the company was founded in 1998, GW Pharmaceuticals has focused on bringing novel prescription medicines to the market, providing patients suffering from serious conditions with valuable medicines that would truly make a difference in their quality of life. GW aims to maximize the value of its products and shareholder returns through rapid economical product development, addressing the needs of the market, and creating commercial partnerships.

GW Pharmaceuticals strives to maintain its position as a world leader in cannabinoid science, as it has developed an international network comprised of the industry’s most established scientists over the years. In 2007, GW and Otsuka collaborated, paving the way for the substantial expansion of the company’s early cannabinoid research activities. The two companies have worked together to research on cannabinoids as potential treatments for disorders of the central nervous system. The company’s in-house program also researches cannabinoids being used as treatments for metabolic disorders such as Type 2 diabetes.

GW’s lead product is Sativex, a treatment for symptom improvement of patients suffering from moderate to severe spasticity due to Multiple Sclerosis. Sativex is currently recommended for approval or already approved for use in 24 countries worldwide. It is currently in Phase III clinical development as treatment for cancer pain.

GW Pharmaceuticals, PLC is licensed to work with controlled substances for purposes of medical research. It continues to focus on its product portfolio of cannabinoid-based medicines in order to meet the needs of patients in an extensive range of medical indications.

Yahoo! Finance: GWPH News

Latest Financial News for GWPH

Buy Marijuana Stocks Now? You'd Have to Be Stoned.

Don't let your investment dollars go to pot

2 Hemp Stocks for Investors Looking for Something Different

in early November, writing this: "Investors need to risk a close below $130 to trade GWPH from the long side. Looking back at the price action since the beginning of November, chart below, we can see traders may have gone long above $150 and then were quickly stopped out with a loss about two weeks later. GWPH is trading above the slightly rising 200-day moving average line and the bullish 50-day average line.

2 Brand-Name Pot Stocks That Will Lose Money in 2020

Being popular within the investment community doesn't mean being profitable.

GW Pharma announces sale of priority review voucher for $105 million

GW Pharmaceuticals Plc said Monday it is selling its Rare Pediatric Disease Priority Review Voucher for $105 million. The company, which was the first to receive U.S. Food and Drug Administration approval for a cannabis-based drug, received the PRV when it was developing that treatment called Epidiolex, which treats seizures associated with two types of rare childhood epilepsy. The PRV program aims to encourage companies to invest in R&D for rare pediatric diseases. The buyer is entitled to a priority, expedited review, with the aim of helping to bring drugs to market that treat rare diseases. "The sale of the PRV provides an important source of non-dilutive capital to help advance our pipeline and to continue to invest in the EPIDIOLEX commercial launch in both the U.S. and Europe," GW Pharma Chief Executive Justin Gover said in a statement. Shares were not yet active premarket, but have gained 42.5% in the last 12 months, while the S&P 500 has gained 2.6%.

GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M

GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), the world leader in the development and commercialization of cannabinoid prescription medicines, today announced that GW Research Ltd. has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $105,000,000.  GW was awarded the voucher under a U.S. Food and Drug Administration (FDA) program intended to encourage the development of treatments for rare pediatric diseases. GW Research Ltd. received the PRV when EPIDIOLEX® (cannabidiol) was approved by the FDA for the treatment of seizures associated with Lennox-Gastaut Syndrome or Dravet syndrome, two rare, severe childhood-onset epilepsies.